Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESSAGE: Met/SGLT-2i/GLP-1RA Triple Therapy in T2DM
NCT07244003Phase 4Recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ganagliflozin and liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huadong Medicine. Primary endpoint: Change of HbA1c compared to baseline at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
ganagliflozinliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07244003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244003.